Loading
Loading
Product image is a representation — actual packaging and label may vary.
Nasal Sprays · 15ml
🕐 Pre-order — ships from 31 August 2026
This product is pre-order only right now. Your order will be dispatched once stock arrives on 31 August 2026.
$106
AUD · 1 pack
Flat rate · ships with your order
DSIP (Delta Sleep-Inducing Peptide) is a neuropeptide studied in preclinical research for its sleep-regulatory and neuromodulatory properties. Research has examined its potential to promote slow-wave delta sleep, modulate stress hormone responses including ACTH and cortisol, reduce oxidative stress, and exhibit antioxidant activity. Studies have also explored potential analgesic and normotensive effects.
Chemical Properties
Research Use Only — Disclaimer
These consumable supplies are intended solely for use in research and laboratory settings. All items are sterile and individually packaged for professional handling. BAC water is for peptide reconstitution purposes only and is not intended for injection without appropriate professional supervision. Not for human or animal consumption in any form.
DSIP
Delta Sleep-Inducing Peptide
DSIP (Delta Sleep-Inducing Peptide) is a synthetic nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1974 from the cerebral venous blood of sleeping rabbits by Schoenenberger et al. at the University of Basel. Despite the name, research has shown it modulates sleep architecture and neuroendocrine function broadly rather than simply inducing sleep, with particularly interesting effects on HPA axis regulation and antioxidant systems.
DSIP modulates the hypothalamic-pituitary-adrenal (HPA) axis, reducing ACTH and cortisol release — an effect relevant to stress-related sleep disruption. It enhances slow-wave (delta) sleep while reducing sleep fragmentation. Antioxidant activity (reducing lipid peroxidation and protecting mitochondrial membranes) has been documented in multiple tissue types. DSIP also interacts with opioid receptor sensitivity, with antagonistic effects at low doses on opioid tolerance development.
Research areas include sleep architecture optimisation, HPA axis dysregulation, chronic stress, cancer-related pain and insomnia, opiate withdrawal symptom mitigation, and menopausal symptom management (Russian clinical studies). Animal longevity studies showed that chronic DSIP administration extended mean and maximum lifespan in mice with reduction in spontaneous tumour incidence.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
